文献速递临床试验与 GCP真实世界研究与卫生经济

髋关节发育不良患者行髋臼周围截骨术联合或不联合关节镜管理:多中心随机对照试验研究方案

Periacetabular osteotomy with or without arthroscopic management in patients with hip dysplasia: study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2020-08-18

本研究为多中心随机对照试验,比较髋臼周围截骨术(PAO)联合髋关节镜与单纯PAO在髋关节发育不良患者中的疗效。主要结局为患者报告的生活质量(iHOT-33),并评估成本效用。假设联合关节镜可改善患者报告结局且具有成本效益。

要点

  • PAO联合关节镜可能改善髋关节发育不良患者的患者报告结局。
  • 需评估联合手术的额外成本是否被临床获益抵消。
  • 联合手术的成本效用需在加拿大医疗体系下验证。

核心结论

  • 假设PAO联合关节镜可带来临床重要改善且具有成本效益,但尚待试验验证。

研究设计与样本

  • 多中心随机对照试验,比较PAO联合关节镜(实验组)与单纯PAO(对照组)。
  • 主要结局为iHOT-33测量的患者报告生活质量,并设多个次要结局和成本效用分析。
  • 亚组每组26例患者接受术前术后T1rho MRI评估软骨质量变化。

关键数值与推荐

  • 主要结局为iHOT-33;次要结局包括四平方步测试、坐立测试、HOOS、PROMIS Global 10、EQ-5D-5L和EQ VAS。
  • 收集手术时间、住院时长、不良事件和卫生服务利用;亚组每组26例进行T1rho MRI。
  • 进行成本效用分析,比较成本和QALYs。

临床怎么用

  • 为髋关节发育不良患者选择PAO联合关节镜或单纯PAO提供证据。
  • 帮助临床决策考虑附加关节镜的获益与成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hip dysplasia is one of the most common causes of hip arthritis. Its incidence is estimated to be between 3.6 and 12.8% (Canadian Institute for Health Information, Hip and knee replacements in Canada, 2017-2018: Canadian joint replacement registry annual report, 2019; Jacobsen and Sonne-Holm, Rheumatology 44:211-8, 2004). The Periacetabular Osteotomy (PAO) has been used successfully for over 30 years (Gosvig et al., J Bone Joint Surg Am 92:1162-9, 2010), but some patients continue to exhibit symptoms post-surgery (Wyles et al., Clin Orthop Relat Res 475:336-50, 2017). A hip arthroscopy, performed using a small camera, allows surgeons to address torn cartilage inside the hip joint. Although both procedures are considered standard of care treatment options, it is unknown whether the addition of hip arthroscopy improves patient outcomes compared to a PAO alone. To delay or prevent future joint replacement surgeries, joint preservation surgery is recommended for eligible patients. While previous studies found an added cost to perform hip arthroscopies, the cost-effectiveness to Canadian Health care system is not known. METHODS: Patients randomized to the experimental group will undergo central compartment hip arthroscopy prior to completion of the PAO. Patients randomized to the control group will undergo isolated PAO. Patient-reported quality of life will be the primary outcome used for comparison between the two treatment groups as measured by The International Hip Outcome Tool (iHOT-33) (Saberi Hosnijeh et al., Arthritis Rheum 69:86-93, 2017). Secondary outcomes will include the four-square step test and sit-to-stand (validated in patients with pre-arthritic hip pain) and hip-specific symptoms and impairment using the HOOS; global health assessment will be compared using the PROMIS Global 10 Score; health status will be assessed using the EQ-5D-5L and EQ VAS questionnaires (Ganz et al., Clin Orthop Relat Res 466:264-72, 2008) pre- and post-operatively. In addition, operative time, hospital length of stay, adverse events, and health services utilization will be collected. A sub-group of patients (26 in each group) will receive a T1rho MRI before and after surgery to study changes in cartilage quality over time. A cost-utility analysis will be performed to compare costs and quality-adjusted life years (QALYs) associated with the intervention. DISCUSSION: We hypothesize that (1) concomitant hip arthroscopy at the time of PAO to address central compartment pathology will result in clinically important improvements in patient-reported outcome measures (PROMs) versus PAO alone, that (2) additional costs associated with hip arthroscopy will be offset by greater clinical improvements in this group, and that (3) combined hip arthroscopy and PAO will prove to be a cost-effective procedure. TRIAL REGISTRATION: ClinicalTrials.gov NCT03481010 . Registered on 6 March 2020. Protocol version: version 3.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wilkin GP, Poitras S, Clohisy J, et al. Periacetabular osteotomy with or without arthroscopic management in patients with hip dysplasia: study protocol for a multicenter randomized controlled trial. Trials. 2020. PMID: 32811527. doi:10.1186/s13063-020-04592-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。